Last reviewed 2026-05-19 · How we verify

Clopiran (CLOPIRAC)

Phase 2 active Small molecule ✓ Verified May 2026

Clopiran (generic name: CLOPIRAC) is a clopirac drug. It is currently in Phase 2 development.

Clopiran is thought to work by interacting with a specific biological target, although its exact mechanism of action is not well understood.

Clopiran is a small molecule with the synonyms BRL 13856, BRL-13856, and Clopirac.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CLOPIRAC
Drug class	clopirac
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and Clopiran is a key that fits into one of those locks. When it binds to the lock, it can either turn it on or off, depending on the type of lock and the key's shape. This can help regulate various bodily functions, but more research is needed to understand exactly how it works.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Clopiran CI brief — competitive landscape report
Clopiran updates RSS · CI watch RSS

Frequently asked questions about Clopiran

What is Clopiran?

Clopiran (CLOPIRAC) is a clopirac drug.

How does Clopiran work?

Clopiran is thought to work by interacting with a specific biological target, although its exact mechanism of action is not well understood.

What is the generic name of Clopiran?

CLOPIRAC is the generic (nonproprietary) name of Clopiran.

What drug class is Clopiran in?

Clopiran belongs to the clopirac class. See all clopirac drugs at /class/clopirac.

What development phase is Clopiran in?

Clopiran is in Phase 2.

Drug class: All clopirac drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing